Theravance to split into two listed companies

(Reuters) – Biopharmaceutical company Theravance Inc said it plans to split into two publicly traded companies, one of which would independently manage the development of the respiratory drugs it is working on with GlaxoSmithKline Plc. The split plan comes after weeks of speculation that the company could be bought by Glaxo, Theravance’s largest shareholder with a stake of about 27 percent. Theravance shares were up about 10 percent at $33.50 in after-hours trading on Thursday. …

Resident doc hours not tied to patient deaths: study

By Andrew M. Seaman New York (Reuters Health) – Restricting the number of hours doctors-in-training are allowed to work without rest hasn’t led to more patient deaths, according to a new study. Researchers found no increase in deaths over the three years following a rules change that restricted resident doctors to working a maximum of 80 hours per week. In fact, the team reports a decline in deaths during the fourth and fifth years. “This study is nice, because it shows that late after the 2003 changes there seems to be an improvement in mortality,” said Dr. …

Sickle cell disease accounts for many priapism cases

By Andrew M. Seaman NEW YORK (Reuters Health) – Thanks to commercials for erectile dysfunction drugs, men know to seek medical attention for “erections lasting more than four hours,” but a new study suggests a blood disorder is the cause of many prolonged erections. While the condition – formally known as priapism – is rare, researchers report in The Journal of Urology that between 14 percent and 30 percent of cases that show up in U.S. emergency rooms are men with sickle-cell disease. …

1 8 9 10 11 12 88